期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 15, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13045-022-01295-3
关键词
Apoptosis; Programmed cell death; BCL2; Venetoclax; Navitoclax; Lymphoma; Chronic lymphocytic leukemia; Non-Hodgkin lymphoma; Multiple myeloma
BH3-mimetics are small molecule inhibitors that restore apoptosis in malignant cells. Venetoclax, the currently approved BH3-mimetic, is highly effective in chronic lymphocytic leukemia and other lymphoid malignancies. Combination with anti-CD20 monoclonal antibodies has shown improved efficacy. Common toxicities include tumor lysis syndrome and myelosuppression, which can be managed with established protocols.
BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal antibodies. In this context, tumour lysis syndrome and myelosuppression are the most commonly encountered toxicities and are readily manageable with established protocols. Venetoclax is active in other lymphoid malignancies including several B cell non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, with the highest intrinsic sensitivity observed in mantle cell lymphoma and Waldenstrom macroglobulinemia. Venetoclax combination with standard regimens in follicular lymphoma, multiple myeloma and aggressive B cell neoplasms has shown some promise, but further studies are required to optimize dose and scheduling to mitigate increased myelosuppression and infection risk, and to find validated biomarkers of venetoclax sensitivity. Future research will focus on overcoming venetoclax resistance, targeting other BCL2 family members and the rational design of synergistic combinations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据